Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 296

1.

IASLC Statement Paper: Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC).

Rolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, Herbst RS, Mok TS, Peled N, Pirker R, Raez LE, Reck M, Riess JW, Sequist LV, Shepherd FA, Sholl LM, Tan DS, Wakelee HA, Wistuba II, Wynes MW, Carbone DP, Hirsch FR, Gandara DR.

J Thorac Oncol. 2018 Jun 6. pii: S1556-0864(18)30680-4. doi: 10.1016/j.jtho.2018.05.030. [Epub ahead of print]

PMID:
29885479
2.

Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF).

Arkenau HT, Martin-Liberal J, Calvo E, Penel N, Krebs MG, Herbst RS, Walgren RA, Widau RC, Mi G, Jin J, Ferry D, Chau I.

Oncologist. 2018 May 31. pii: theoncologist.2018-0044. doi: 10.1634/theoncologist.2018-0044. [Epub ahead of print]

PMID:
29853658
3.

Defining and Understanding Adaptive Resistance in Cancer Immunotherapy.

Kim TK, Herbst RS, Chen L.

Trends Immunol. 2018 May 22. pii: S1471-4906(18)30097-8. doi: 10.1016/j.it.2018.05.001. [Epub ahead of print] Review.

PMID:
29802087
4.

ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection.

Wu YL, Herbst RS, Mann H, Rukazenkov Y, Marotti M, Tsuboi M.

Clin Lung Cancer. 2018 Jul;19(4):e533-e536. doi: 10.1016/j.cllc.2018.04.004. Epub 2018 May 1.

5.

Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.

Kadara H, Choi M, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Yoo Y, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee J, Lifton RP, Wistuba II, Herbst RS.

Ann Oncol. 2018 Apr 1;29(4):1072. doi: 10.1093/annonc/mdx062. No abstract available.

PMID:
29688333
6.

Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non-Small Cell Lung Cancer.

Gettinger SN, Wurtz A, Goldberg SB, Rimm D, Schalper K, Kaech S, Kavathas P, Chiang A, Lilenbaum R, Zelterman D, Politi K, Herbst RS.

J Thorac Oncol. 2018 Jun;13(6):831-839. doi: 10.1016/j.jtho.2018.03.008. Epub 2018 Mar 22.

PMID:
29578107
7.

Treatment of Advanced Non-Small Cell Lung Cancer in 2018.

Doroshow DB, Herbst RS.

JAMA Oncol. 2018 Apr 1;4(4):569-570. doi: 10.1001/jamaoncol.2017.5190. No abstract available.

PMID:
29494728
8.

The biology and management of non-small cell lung cancer.

Herbst RS, Morgensztern D, Boshoff C.

Nature. 2018 Jan 24;553(7689):446-454. doi: 10.1038/nature25183. Review.

PMID:
29364287
9.

Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA.

Goldberg SB, Narayan A, Kole AJ, Decker RH, Teysir J, Carriero NJ, Lee A, Nemati R, Nath SK, Mane SM, Deng Y, Sukumar N, Zelterman D, Boffa DJ, Politi K, Gettinger SN, Wilson LD, Herbst RS, Patel AA.

Clin Cancer Res. 2018 Apr 15;24(8):1872-1880. doi: 10.1158/1078-0432.CCR-17-1341. Epub 2018 Jan 12.

PMID:
29330207
10.

Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis.

Lee CK, Man J, Lord S, Cooper W, Links M, Gebski V, Herbst RS, Gralla RJ, Mok T, Yang JC.

JAMA Oncol. 2018 Feb 1;4(2):210-216. doi: 10.1001/jamaoncol.2017.4427.

PMID:
29270615
11.

Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer.

Villarroel-Espindola F, Yu X, Datar I, Mani N, Sanmamed M, Velcheti V, Syrigos K, Toki M, Zhao H, Chen L, Herbst RS, Schalper KA.

Clin Cancer Res. 2018 Apr 1;24(7):1562-1573. doi: 10.1158/1078-0432.CCR-17-2542. Epub 2017 Dec 4.

PMID:
29203588
12.

Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.

Herbst RS, Redman MW, Kim ES, Semrad TJ, Bazhenova L, Masters G, Oettel K, Guaglianone P, Reynolds C, Karnad A, Arnold SM, Varella-Garcia M, Moon J, Mack PC, Blanke CD, Hirsch FR, Kelly K, Gandara DR.

Lancet Oncol. 2018 Jan;19(1):101-114. doi: 10.1016/S1470-2045(17)30694-0. Epub 2017 Nov 20.

13.

Immuno-thermal ablations - boosting the anticancer immune response.

Slovak R, Ludwig JM, Gettinger SN, Herbst RS, Kim HS.

J Immunother Cancer. 2017 Oct 17;5(1):78. doi: 10.1186/s40425-017-0284-8. Review.

14.

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer.

Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick MA, Du VY, Schlessinger J, Goldberg SB, Chiang A, Sanmamed MF, Melero I, Agorreta J, Montuenga LM, Lifton R, Ferrone S, Kavathas P, Rimm DL, Kaech SM, Schalper K, Herbst RS, Politi K.

Cancer Discov. 2017 Dec;7(12):1420-1435. doi: 10.1158/2159-8290.CD-17-0593. Epub 2017 Oct 12.

PMID:
29025772
15.

Lung Endothelial MicroRNA-1 Regulates Tumor Growth and Angiogenesis.

Korde A, Jin L, Zhang JG, Ramaswamy A, Hu B, Kolahian S, Guardela BJ, Herazo-Maya J, Siegfried JM, Stabile L, Pisani MA, Herbst RS, Kaminski N, Elias JA, Puchalski JT, Takyar SS.

Am J Respir Crit Care Med. 2017 Dec 1;196(11):1443-1455. doi: 10.1164/rccm.201610-2157OC.

PMID:
28853613
16.

JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non-Small Cell Lung Cancer.

Shien K, Papadimitrakopoulou VA, Ruder D, Behrens C, Shen L, Kalhor N, Song J, Lee JJ, Wang J, Tang X, Herbst RS, Toyooka S, Girard L, Minna JD, Kurie JM, Wistuba II, Izzo JG.

Mol Cancer Ther. 2017 Oct;16(10):2234-2245. doi: 10.1158/1535-7163.MCT-17-0148. Epub 2017 Jul 20.

PMID:
28729401
17.

The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer.

Cascone T, Xu L, Lin HY, Liu W, Tran HT, Liu Y, Howells K, Haddad V, Hanrahan E, Nilsson MB, Cortez MA, Giri U, Kadara H, Saigal B, Park YY, Peng W, Lee JS, Ryan AJ, Jüergensmeier JM, Herbst RS, Wang J, Langley RR, Wistuba II, Lee JJ, Heymach JV.

Clin Cancer Res. 2017 Sep 15;23(18):5489-5501. doi: 10.1158/1078-0432.CCR-16-3216. Epub 2017 May 30.

PMID:
28559461
18.

B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes.

Altan M, Pelekanou V, Schalper KA, Toki M, Gaule P, Syrigos K, Herbst RS, Rimm DL.

Clin Cancer Res. 2017 Sep 1;23(17):5202-5209. doi: 10.1158/1078-0432.CCR-16-3107. Epub 2017 May 24.

PMID:
28539467
19.

Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI-Cardiovascular Medical Research and Education Fund Workshop Report.

Newman JH, Rich S, Abman SH, Alexander JH, Barnard J, Beck GJ, Benza RL, Bull TM, Chan SY, Chun HJ, Doogan D, Dupuis J, Erzurum SC, Frantz RP, Geraci M, Gillies H, Gladwin M, Gray MP, Hemnes AR, Herbst RS, Hernandez AF, Hill NS, Horn EM, Hunter K, Jing ZC, Johns R, Kaul S, Kawut SM, Lahm T, Leopold JA, Lewis GD, Mathai SC, McLaughlin VV, Michelakis ED, Nathan SD, Nichols W, Page G, Rabinovitch M, Rich J, Rischard F, Rounds S, Shah SJ, Tapson VF, Lowy N, Stockbridge N, Weinmann G, Xiao L.

Am J Respir Crit Care Med. 2017 Jun 15;195(12):1661-1670. doi: 10.1164/rccm.201701-0150WS.

20.

Extracellular Matrix Receptor Expression in Subtypes of Lung Adenocarcinoma Potentiates Outgrowth of Micrometastases.

Stevens LE, Cheung WKC, Adua SJ, Arnal-Estapé A, Zhao M, Liu Z, Brewer K, Herbst RS, Nguyen DX.

Cancer Res. 2017 Apr 15;77(8):1905-1917. doi: 10.1158/0008-5472.CAN-16-1978. Epub 2017 Feb 14. Erratum in: Cancer Res. 2018 Feb 1;78(3):840.

21.

Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function.

Choi M, Kadara H, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Kim K, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee J, Lifton RP, Herbst RS, Wistuba II.

Ann Oncol. 2017 Jan 1;28(1):83-89. doi: 10.1093/annonc/mdw437.

PMID:
28177435
22.

Association of Delayed Adjuvant Chemotherapy With Survival After Lung Cancer Surgery.

Salazar MC, Rosen JE, Wang Z, Arnold BN, Thomas DC, Herbst RS, Kim AW, Detterbeck FC, Blasberg JD, Boffa DJ.

JAMA Oncol. 2017 May 1;3(5):610-619. doi: 10.1001/jamaoncol.2016.5829.

23.

PS01.62: Long-Term Safety and Clinical Activity of Atezolizumab Monotherapy in Metastatic NSCLC: Final Results from a Phase Ia Study: Topic: Medical Oncology.

Gordon MS, Herbst RS, Horn L, Soria JC, Gandhi L, Felip E, Sequist L, Spigel DR, Antonia SJ, Balmanoukian A, Cassier P, Liu B, Kowanetz M, O'Hear C, Fassò M, Sandler A, Gettinger SN.

J Thorac Oncol. 2016 Nov;11(11S):S309-S310. doi: 10.1016/j.jtho.2016.09.097. Epub 2016 Oct 28. No abstract available.

24.

PS01.56: IMpower110: Phase III Trial Comparing 1L Atezolizumab with Chemotherapy in PD-L1-Selected Chemotherapy-Naive NSCLC Patients: Topic: Medical Oncology.

Herbst RS, De Marinis F, Jassem J, Lam S, Mocci S, Sandler A, Lopez-Chavez A, Deng Y, Giaccone G, Spigel DR.

J Thorac Oncol. 2016 Nov;11(11S):S304-S305. doi: 10.1016/j.jtho.2016.09.091. Epub 2016 Oct 28. No abstract available.

25.

Evolving Treatment Options for Lung Cancer.

Morgensztern D, Herbst RS.

Hematol Oncol Clin North Am. 2017 Feb;31(1):xiii-xiv. doi: 10.1016/j.hoc.2016.09.001. No abstract available.

PMID:
27912837
26.

Immunotherapy in Lung Cancer.

Du L, Herbst RS, Morgensztern D.

Hematol Oncol Clin North Am. 2017 Feb;31(1):131-141. doi: 10.1016/j.hoc.2016.08.004. Review.

PMID:
27912829
27.

Diminished but not dead: chemotherapy for the treatment of NSCLC.

Herbst RS, Sznol M.

Lancet Oncol. 2016 Nov;17(11):1464-1465. doi: 10.1016/S1470-2045(16)30524-1. No abstract available.

PMID:
27819227
28.

Smoking Cessation, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.

Shields PG, Herbst RS, Arenberg D, Benowitz NL, Bierut L, Luckart JB, Cinciripini P, Collins B, David S, Davis J, Hitsman B, Hyland A, Lang M, Leischow S, Park ER, Purcell WT, Selzle J, Silber A, Spencer S, Tanvetyanon T, Tiep B, Tindle HA, Tucker-Seeley R, Urbanic J, Hooper MW, Weksler B, Whitlock CW, Wood DE, Burns J, Scavone J.

J Natl Compr Canc Netw. 2016 Nov;14(11):1430-1468.

PMID:
27799513
29.

Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.

Kadara H, Choi M, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Yoo Y, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee J, Lifton RP, Wistuba II, Herbst RS.

Ann Oncol. 2017 Jan 1;28(1):75-82. doi: 10.1093/annonc/mdw436.

30.

P2.41 (also presented as PD1.06): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment: Track: Immunotherapy.

Herbst RS, Baas P, Perez-Gracia JL, Felip E, Kim DW, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, Surmont V, De Castro G Jr, Garrido M, Shentu Y, Dolled-Filhart M, Im E, Garon EB.

J Thorac Oncol. 2016 Oct;11(10S):S242-S243. doi: 10.1016/j.jtho.2016.08.112. Epub 2016 Sep 22. No abstract available.

31.

PD1.06 (also presented as P2.41): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment.

Herbst RS, Baas P, Perez-Gracia JL, Felip E, Kim DW, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, Surmont V, De Castro G Jr, Garrido M, Shentu Y, Dolled-Filhart M, Im E, Garon EB.

J Thorac Oncol. 2016 Oct;11(10S):S174-S175. doi: 10.1016/j.jtho.2016.08.014. Epub 2016 Sep 22. No abstract available.

32.

Bayesian Two-stage Biomarker-based Adaptive Design for Targeted Therapy Development.

Gu X, Chen N, Wei C, Liu S, Papadimitrakopoulou VA, Herbst RS, Lee JJ.

Stat Biosci. 2016 Jun;8(1):99-128. Epub 2014 Dec 4.

33.

The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer.

Papadimitrakopoulou V, Lee JJ, Wistuba II, Tsao AS, Fossella FV, Kalhor N, Gupta S, Byers LA, Izzo JG, Gettinger SN, Goldberg SB, Tang X, Miller VA, Skoulidis F, Gibbons DL, Shen L, Wei C, Diao L, Peng SA, Wang J, Tam AL, Coombes KR, Koo JS, Mauro DJ, Rubin EH, Heymach JV, Hong WK, Herbst RS.

J Clin Oncol. 2016 Aug 1. pii: JCO660084. [Epub ahead of print]

34.

Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer.

Schalper KA, Carvajal-Hausdorf D, McLaughlin J, Altan M, Velcheti V, Gaule P, Sanmamed MF, Chen L, Herbst RS, Rimm DL.

Clin Cancer Res. 2017 Jan 15;23(2):370-378. doi: 10.1158/1078-0432.CCR-16-0150. Epub 2016 Jul 20.

35.

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.

Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, Tsiouris AJ, Cohen J, Vortmeyer A, Jilaveanu L, Yu J, Hegde U, Speaker S, Madura M, Ralabate A, Rivera A, Rowen E, Gerrish H, Yao X, Chiang V, Kluger HM.

Lancet Oncol. 2016 Jul;17(7):976-983. doi: 10.1016/S1470-2045(16)30053-5. Epub 2016 Jun 3.

36.

Nivolumab and Pembrolizumab for Non-Small Cell Lung Cancer.

Morgensztern D, Herbst RS.

Clin Cancer Res. 2016 Aug 1;22(15):3713-7. doi: 10.1158/1078-0432.CCR-15-2998. Epub 2016 Jun 1. Review.

37.

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016.

Tan DS, Yom SS, Tsao MS, Pass HI, Kelly K, Peled N, Yung RC, Wistuba II, Yatabe Y, Unger M, Mack PC, Wynes MW, Mitsudomi T, Weder W, Yankelevitz D, Herbst RS, Gandara DR, Carbone DP, Bunn PA Jr, Mok TS, Hirsch FR.

J Thorac Oncol. 2016 Jul;11(7):946-63. doi: 10.1016/j.jtho.2016.05.008. Epub 2016 May 23. Review.

38.

GSK-3α Is a Novel Target of CREB and CREB-GSK-3α Signaling Participates in Cell Viability in Lung Cancer.

Park SA, Lee JW, Herbst RS, Koo JS.

PLoS One. 2016 Apr 6;11(4):e0153075. doi: 10.1371/journal.pone.0153075. eCollection 2016.

39.

Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma.

Hedberg ML, Goh G, Chiosea SI, Bauman JE, Freilino ML, Zeng Y, Wang L, Diergaarde BB, Gooding WE, Lui VW, Herbst RS, Lifton RP, Grandis JR.

J Clin Invest. 2016 Apr 1;126(4):1606. doi: 10.1172/JCI86862. Epub 2016 Apr 1. No abstract available.

40.

Scientific Advances in Lung Cancer 2015.

Tsao AS, Scagliotti GV, Bunn PA Jr, Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan AU, McWilliams A, Tsao MS, Adusumilli PS, Rami-Porta R, Asamura H, Van Schil PE, Darling GE, Ramalingam SS, Gomez DR, Rosenzweig KE, Zimmermann S, Peters S, Ignatius Ou SH, Reungwetwattana T, Jänne PA, Mok TS, Wakelee HA, Pirker R, Mazières J, Brahmer JR, Zhou Y, Herbst RS, Papadimitrakopoulou VA, Redman MW, Wynes MW, Gandara DR, Kelly RJ, Hirsch FR, Pass HI.

J Thorac Oncol. 2016 May;11(5):613-38. doi: 10.1016/j.jtho.2016.03.012. Epub 2016 Mar 22. Review.

41.

Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research.

Schalper KA, Kaftan E, Herbst RS.

Clin Cancer Res. 2016 May 1;22(9):2102-4. doi: 10.1158/1078-0432.CCR-16-0169. Epub 2016 Mar 8.

42.

Research Priorities, Measures, and Recommendations for Assessment of Tobacco Use in Clinical Cancer Research.

Land SR, Toll BA, Moinpour CM, Mitchell SA, Ostroff JS, Hatsukami DK, Duffy SA, Gritz ER, Rigotti NA, Brandon TH, Prindiville SA, Sarna LP, Schnoll RA, Herbst RS, Cinciripini PM, Leischow SJ, Dresler CM, Fiore MC, Warren GW.

Clin Cancer Res. 2016 Apr 15;22(8):1907-13. doi: 10.1158/1078-0432.CCR-16-0104. Epub 2016 Feb 17.

43.

Immune checkpoint therapy for non-small-cell lung cancer: an update.

Xia B, Herbst RS.

Immunotherapy. 2016;8(3):279-98. doi: 10.2217/imt.15.123. Epub 2016 Feb 9. Review.

PMID:
26860624
44.

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G Jr, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB.

Lancet. 2016 Apr 9;387(10027):1540-50. doi: 10.1016/S0140-6736(15)01281-7. Epub 2015 Dec 19.

PMID:
26712084
45.

Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma.

Hedberg ML, Goh G, Chiosea SI, Bauman JE, Freilino ML, Zeng Y, Wang L, Diergaarde BB, Gooding WE, Lui VW, Herbst RS, Lifton RP, Grandis JR.

J Clin Invest. 2016 Jan;126(1):169-80. doi: 10.1172/JCI82066. Epub 2015 Nov 30. Erratum in: J Clin Invest. 2016 Apr 1;126(4):1606.

46.

Lung-MAP--framework, overview, and design principles.

Ferrarotto R, Redman MW, Gandara DR, Herbst RS, Papadimitrakopoulou VA.

Chin Clin Oncol. 2015 Sep;4(3):36. doi: 10.3978/j.issn.2304-3865.2015.09.02. Review.

47.

From the Guest Editors: Progress and Future Directions for the Treatment of Advanced Lung Cancer.

Goldberg SB, Herbst RS.

Cancer J. 2015 Sep-Oct;21(5):365. doi: 10.1097/PPO.0000000000000152. No abstract available.

PMID:
26389759
48.

EGFR Mutations in Non-Small-Cell Lung Cancer: Find, Divide, and Conquer.

Morgensztern D, Politi K, Herbst RS.

JAMA Oncol. 2015 May;1(2):146-8. doi: 10.1001/jamaoncol.2014.278. No abstract available.

PMID:
26181013
49.

EGFR tyrosine kinase inhibitors in squamous cell lung cancer.

Hirsch FR, Herbst RS, Gandara DR.

Lancet Oncol. 2015 Aug;16(8):872-3. doi: 10.1016/S1470-2045(15)00126-6. Epub 2015 Jul 5. No abstract available.

PMID:
26156654
50.

E2F8 as a Novel Therapeutic Target for Lung Cancer.

Park SA, Platt J, Lee JW, López-Giráldez F, Herbst RS, Koo JS.

J Natl Cancer Inst. 2015 Jun 18;107(9). pii: djv151. doi: 10.1093/jnci/djv151. Print 2015 Sep.

Supplemental Content

Loading ...
Support Center